OVERVIEW

  • Over 20 million US adults and youth suffer from substance use disorders (SUDs) and substance use (SU) related problems. However, most people with SUDs never receive SUD treatment.
  • Historically, research on SUDs has focused on the small minority of patients with SUDs who are seeking, or already engaged in, specialty SUD treatment.
  • The overall goal of the Addictions Research Network is to conduct cutting edge research to improve outcomes in all patients with SU/SUD who are seen in medical settings.

Cynthia Campbell, PhD, MPH


Constance Weisner, DrPH, MSW


Katharine Bradley, MD, MPH 

ACTIVE PROJECTS 

The Addiction Research Network is leading a number of studies that leverage the scientific and data resources of the collaborating systems. Three are highlighted below.

Cynthia Campbell, Constance Weisner and Katharine Bradley lead the Health Systems Node (HSN) of NIDA's Clinical Trial Network (CTN) and provide overall leadership for the Addiction Research Network.

  • The goals of the HSN of the National Institute on Drug Abuse Clinical Trials Network are to improve access to care for the many people whose SU/SUDs are unrecognized, overlooked, and/or untreated and to improve acceptability of SUD treatment, thereby reaching more people.  
  • The long-term vision is for health systems to address all patients' SU/SUDs in an integrated, effective manner and to offer a range of innovative interventions. The HSN research agenda is focused on identifying effective practices for patients with SU/SUDs, designing and testing sustainable ways to integrate those practices into medical care, and developing and disseminating high quality methods to support this research.  
  • Projects led by the CTN HSN are listed below and described in further detail here.

LEARN MORE

  • The main website for the CTN Health Systems Node includes an extensive bibliography of publications
  • HSN sites and biographies for each of the principal and site investigators are available here
  • Contact the Network to learn more about collaboration opportunities and current activities

Stacy Sterling leads the Adolescent Substance Use Problem Predictive Analytics Project.

  • The objective of this project is to develop predictive risk profiles of clinical and demographic characteristics which can be used by health systems and other youth-serving organizations to identify children and adolescents at greatest risk of developing substance use problems, for targeted prevention and early intervention efforts.
  • This study is the first of its kind to develop a predictive model for the development of substance use problems in adolescents, which health care systems and providers will be able to use to increase their capacity to deliver quality prevention services and care to youths at risk of developing substance use problems.

Bobbi Jo Yarborough and Denise Boudreau lead The MUSE study, a prospective investigation of the risks of opioid misuse, abuse, and addiction among patients treated with extended-release/long acting (ER/LA) opioids for the treatment of chronic pain.

  • The primary objective is to quantify the serious risks of misuse, abuse, and addiction associated with long-term use of opioid analgesics for management of chronic pain among patients newly prescribed
    ER/LA opioid products.
  • This multi-site research study is comprised of both a prospective longitudinal study that will estimate the incidence of misuse, abuse and addiction associated with long-term use of ER/LA opioids for chronic pain, and a cross-sectional study that will estimate the prevalence of misuse, abuse and addition associated with long-term use of opioids.
  • Source of Funding: This project is being conducted as part of an FDA-required postmarketing study for extended-release and long-acting opioid analgesics being implemented by the Opioid Postmarketing Consortium (OPC) consisting of the following companies: Allergan; Collegium Pharmaceutical, Inc.; Daiichi Sankyo, Inc.; Depomed, Inc.; Egalet Corporation; Endo Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mallinckrodt, Inc.; Pernix Therapeutics Holdings, Inc.; Pfizer, Inc.; Purdue Pharma, LP.; West-Ward Pharmaceuticals Corp. 
  • HCSRN sites participating in the study include Geisinger Health System (site PI: Joe Boscarino), Henry Ford Health Systems (site PI: Brian Ahmedani), Meyers Primary Care Institute (site PI: Susan Andrade), Kaiser Permanente Northwest (site PI: BobbiJo Yarborough), Kaiser Permanente Southern California (site PI: Rulin Hechter), and Kaiser Permanente Washington (site PI: Denise Boudreau).